Objectives: To study the ex vivo interleukin (IL)-1beta and IL-6 production of monocytes in bipolar disorder (BD) patients in the absence/presence of lithium.
Methods: Monocytes of outpatients with DSM-IV BD (n=80, of whom 64 were lithium-treated) and of healthy control subjects (n=59) were cultured in vitro and exposed (24 h) or not exposed to lipopolysaccharide (LPS) and/or graded concentrations of lithium chloride (LiCl). IL-1beta and IL-6 production was assessed by enzyme-linked immunosorbent assay (ELISA) (supernatants).
Results: Monocytes stimulated by LPS from non-lithium-treated bipolar patients were characterized by an abnormal IL-1beta/IL-6 production ratio, i.e., low IL-1beta and high IL-6 production. Lithium treatment increased IL-1beta and decreased IL-6 production and thus restored the aberrant ratio. In vitro exposure of monocytes to LiCl did not have the same effects as lithium treatment: the procedure decreased IL-1beta production and had minimal effects on IL-6 production.
Conclusions: Blood monocytes have an altered proinflammatory status in BD. Lithium treatment restores this altered status. Short-term in vitro exposure of monocytes to lithium has other effects than lithium treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1399-5618.2007.00444.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lithium-induced nephrogenic diabetes insipidus following improved medication compliance: a case report.
J Med Case Rep
January 2025
Department of Internal Medicine, University of Illinois College of Medicine, Peoria, IL, 61637, USA.
Background: Nephrogenic diabetes insipidus is a rare, often underrecognized complication of long-term lithium therapy. Lithium-induced nephrogenic diabetes insipidus results from chronic renal exposure, leading to significant polyuria, dehydration, and hypernatremia.
Case Presentation: We describe a case of a 55-year-old White caucasian male with a schizoaffective disorder managed with lithium who presented with altered mental status and electrolyte abnormalities following a recent stroke.
Lithium compromises the bioenergetic reserve of cardiomyoblasts mitochondria.
J Bioenerg Biomembr
January 2025
Institute of Molecular Physiology and Genetics, Centre of Biosciences of the Slovak Academy of Sciences, Dubravska cesta 9, Bratislava, 840 05, Slovakia.
Lithium is used in the long-term treatment of bipolar disorder, exhibiting a beneficial effect on the neuronal cells. The concentration of lithium in the blood serum can vary and can easily approach a level that is related to cardiotoxic adverse effects. This is due to its narrow therapeutic index.
View Article and Find Full Text PDFA Retrospective Study of the Influence of Life Events and Social Support on Relapses and Recurrences in Older Patients with Bipolar Disorder.
Geriatrics (Basel)
January 2025
Parnassia Psychiatric Institute, Mangostraat 1, 2552 KS The Hague, The Netherlands.
: Life events and lack of social support are risk factors for a relapse or recurrence in patients with a bipolar disorder, yet studies focusing on older adults remain limited. Our aim was to investigate the influence of life events and social support on the course of bipolar disorder in older adults. : A retrospective cohort study included patients aged 55 years and older in treatment for bipolar disorder and who used lithium.
View Article and Find Full Text PDFStabilizing Layered Oxide Cathodes Based on Universal Surface Residual Alkali Conversion Chemistry for Rechargeable Secondary Batteries.
Adv Mater
January 2025
College of Chemistry and Materials Engineering, Wenzhou University, Wenzhou, 325035, P. R. China.
Layered transition metal oxides (LTMOs) are attractive cathode candidates for rechargeable secondary batteries because of their high theoretical capacity. Unfortunately, LTMOs suffer from severe capacity attenuation, voltage decay, and sluggish kinetics, resulting from irreversible lattice oxygen evolution and unstable cathode-electrolyte interface. Besides, LTMOs accumulate surface residual alkali species, like hydroxides and carbonates, during synthesis, limiting their practical application.
View Article and Find Full Text PDFMethionine Sulfoximine as a Tool for Studying Temporal Lobe Epilepsy: Initiator, Developer, Attenuator.
Neurochem Res
January 2025
Department of Pathophysiology, Medical University of Lublin, 20-090, Lublin, Poland.
Methionine sulfoximine (MSO) is a compound originally discovered as a byproduct of agene-based milled flour maturation. MSO irreversibly inhibits the astrocytic enzyme glutamine synthase (GS) but also interferes with the transport of glutamine (Gln) and of glutamate (Glu), and γ-aminobutyric acid (GABA) synthesized within the Glu/Gln-GABA cycle, in this way dysregulating neurotransmission balance in favor of excitation. No wonder that intraperitoneal administration of MSO has long been known to induce behavioral and/or electrographic seizures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!